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Abstract
Background: Complementarity-determining regions (CDRs) are immunoglobulin (Ig) hypervariable domains that determine
specific antibody (Ab) binding. We have shown that synthetic CDR-related peptides and many decapeptides spanning the
variable region of a recombinant yeast killer toxin-like antiidiotypic Ab are candidacidal in vitro. An alanine-substituted
decapeptide from the variable region of this Ab displayed increased cytotoxicity in vitro and/or therapeutic effects in vivo
against various bacteria, fungi, protozoa and viruses. The possibility that isolated CDRs, represented by short synthetic
peptides, may display antimicrobial, antiviral and antitumor activities irrespective of Ab specificity for a given antigen is
addressed here.
Methodology/Principal Findings: CDR-based synthetic peptides of murine and human monoclonal Abs directed to: a) a
protein epitope of Candida albicans cell wall stress mannoprotein; b) a synthetic peptide containing well-characterized B-
cell and T-cell epitopes; c) a carbohydrate blood group A substance, showed differential inhibitory activities in vitro, ex vivo
and/or in vivo against C. albicans, HIV-1 and B16F10-Nex2 melanoma cells, conceivably involving different mechanisms of
action. Antitumor activities involved peptide-induced caspase-dependent apoptosis. Engineered peptides, obtained by
alanine substitution of Ig CDR sequences, and used as surrogates of natural point mutations, showed further differential
increased/unaltered/decreased antimicrobial, antiviral and/or antitumor activities. The inhibitory effects observed were
largely independent of the specificity of the native Ab and involved chiefly germline encoded CDR1 and CDR2 of light and
heavy chains.
Conclusions/Significance: The high frequency of bioactive peptides based on CDRs suggests that Ig molecules are sources
of an unlimited number of sequences potentially active against infectious agents and tumor cells. The easy production and
low cost of small sized synthetic peptides representing Ig CDRs and the possibility of peptide engineering and chemical
optimization associated to new delivery mechanisms are expected to give rise to a new generation of therapeutic agents.
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Introduction
Immunoglobulins are composed of polymorphic heavy and light
chains. The idiotypic variability is related to the diversity of the
antigen binding site and in particular to the hypervariable domains
called complementarity-determining regions (CDRs). There are 6
CDRs in both variable regions of light (VL) and heavy chains (VH)
with background variability on each side of the CDRs. Antibodies
(Abs) of different specificities can assemble identical VL domains
with different VH domains. The framework sequences between
CDRs can be similar or identical.
Idiotypic vaccination with a murine monoclonal Ab (mAb KT4),
that neutralizes the wide-spectrum antimicrobial activity of a yeast
killer toxin (KT) against eukaryotic and prokaryotic microorganisms
presenting specific cell wall receptors (KTR), elicited the production
of a special sub-set of antiidiotypic Abs (KT-antiId) characterized by
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in vitro microbicidal and in vivo therapeutic effects [1]. Abs
functionally mimetizing KT were detected in the serum or
secretions of animals and humans experimentally or naturally
infected with KTR-bearing microorganisms (KT-Abs) and have
been produced in the monoclonal (KT-mAb) and recombinant
(KT-scFv) formats. KT-Abs, KT-mAb and KT-scFv conferred
passive immunoprotection in experimental models of mucosal and
systemic fungal infections [2–4].
The peptides corresponding to the CDRs of KT-scFv, as well as
a series of two-residue displaced overlapping decapeptides
spanning the variable region were synthesized. All the synthetic
CDRs and most of the related decapeptides showed a fungicidal
effect against Candida albicans in vitro [5]. The most in vitro and in vivo
active fragment (P6), including seven amino acids of the
framework region and the first three residues of the light chain
CDR1 of KT-scFv, was well represented among the sequences of
many unrelated Abs. A killer decapeptide (KP) generated by
alanine substitution of the first aminoacid of P6 had increased
candidacidal activity in vitro. Significantly, KP exerted therapeutic
effect in well established murine models of vaginal and systemic
candidiasis, cryptococcosis and paracoccidioidomycosis [5–7]. KP,
KT-Abs, KT-mAb and KT-scFv exerted a broad microbicidal
activity in vitro including pathogenic bacteria and protozoa [8,9].
Surprisingly, based on the sequence homology of P6 with critical
segments of the gp160 precursor, KP proved to inhibit the in vitro
and ex vivo replication of HIV-1 [10].
A mAb (C7), raised against C. albicans cell wall stress
mannoprotein, a major target of human secretory IgA in the
course of oral and vaginal candidiasis, has been recently described
[11]. As a polyreactive IgM, mAb C7 cross-reacted with cell wall
proteins of C. albicans Als3 and enolase, as well as with the nuclear
pore complex Nup88 [12,13]. MAb C7 is the first Ab able to exert
three different antifungal activities against C. albicans, such as
inhibition of germination and adhesion and a direct fungicidal
effect which extended to C. lusitaniae, Cryptococcus neoformans,
Aspergillus fumigatus, and Scedosporium prolificans, suggesting a
pleiotropic mode of action [11]. Recently, mAb C7 proved to be
protective in a murine model of systemic candidiasis [14].
As a proof of concept of the extrinsic potential of Ab fragments,
we now report on the differential antimicrobial, antiviral and
antitumor activities of synthetic peptides with sequences identical
to CDRs of the light chain (L1, L2 and L3) and heavy chain (H1,
H2 and H3) of: a) mAb C7; b) mouse mAb pc42 (IgM), directed to
a synthetic peptide containing the surface antigen of hepatitis B
virus and the T-helper-cell epitope from the circumsporozoite
protein of Plasmodium falciparum, sharing H1 and H2 with mAb C7
[15]; and c) a human IgM mAb (HuA) specific for difucosyl human
blood group A substance sharing no CDR homology with either
mAb C7 or mAb pc42 [16].
Results
Anticandidal activities of CDR-based synthetic peptides
The in vitro microbicidal activity of mAb C7, mAb pc42 and
mAb HuA CDR-based synthetic peptides at 100 mg/mL, and the
EC50 of CDRs that exhibited a significant activity against C.
albicans UP10 are shown in Table 1. The most active CDR
peptides were mAb pc42 L1, mAb C7/pc42 H2 and HuA L3
(Fig. 1A). Similar results were obtained with C. albicans NCPF 3153
(data not shown). Most H2 alanine-substituted derivatives (asd) had
activities similar to H2, but some showed modulating effects
(Table 2). Substitution of the last residue in H2 (K16A) resulted in
a fundamental loss of activity whereas substitution of the previous
amino acid (F15A) gave rise to the highest candidacidal derivative.
MAb C7/pc42 H1 and H2, and mAb C7 L1 CDRs also
conferred protection against invasive candidiasis. Treatment of
infected animals with the peptides led to increased survival time
with some fully protected animals at the end of the experiment
(Fig. 1B). The survival curves correlated well with differences in
fungal burden in kidney tissue, particularly in animals treated with
mAb C7 L1 CDR. On day 5 post-infection, the CFU counts in
kidney tissue were 160.3646.6, 53.4652.0, 119.6635.5, and
133.4643.5 for mice treated with saline, mAb C7 L1, mAb C7/
pc42 H1 and H2 CDRs, respectively. When compared with the
results obtained in saline treated animals, only the results from
mice treated with mAb C7 L1 were statistically significant
(p = 0.02).
Anti HIV-1 activity of CDR-based synthetic peptides
The ex vivo and in vitro activities of synthetic peptides
corresponding to mAb C7, mAb pc42, mAb HuA CDRs and
asd of mAb C7/pc42 H1 against HIV-1 are shown in Tables 3 and
4. The kinetics of viral Ag production in untreated cultures
corresponded to 100% of viral production. Results are represen-
Figure 1. Anticandidal activities of mAb CDRs. A. In vitro
candidacidal activity of three different CDR peptides (HuA L3, pc42
L1, C7/pc42 H2) against Candida albicans UP 10 cells as shown by CFU
assay. C. albicans cells were treated with 100 mg/ml of each peptide in
distilled water (upper) in comparison with distilled water only (lower).
Each plate is representative of an assay carried out in triplicate; B. Effect
of mAb C7/pc42 H1 and H2 and mAb C7 L1 CDRs on the survival curve
of mice (11–12 animals/group) infected intravenously with 56105 yeast
cells of C. albicans. The survival curve of mAb C7 L1-treated animals was
significantly different (p = 0.01) from that of control mice. MST6SE
mean survival time6standard errors.
doi:10.1371/journal.pone.0002371.g001
Biological Effects of Ig CDRs
PLoS ONE | www.plosone.org 2 June 2008 | Volume 3 | Issue 6 | e2371
tative of 4 independent experiments performed for each assay
condition. Percent values of HIV-1 inhibition express the mean of
3 determinations observed on day 10 of cultures. In ex vivo
conditions, R5 HIV-1 replication in treated cultures was inhibited
(.50%) by mAb C7/pc42 H1, and even more (about 90%) by
mAb pc42 L1. In addition, a derivative of mAb C7/pc42 H1, H1
Y3A, had enhanced inhibitory effect on HIV-1, while G1A and
H5A lost their activity, showing that substitution of one residue
can influence the antiviral property. In experimental conditions
allowing the infection of healthy PHA-activated PBMCs, the
peptide-mediated effect was dependent on the HIV-1 phenotype.
As shown in Table 3, by using the BaL strain (R5) results similar to
the ones of the endogenous replication model were obtained. In
contrast, except for mAb C7 H3, all peptides analyzed using IIIB
strain (X4) were unable to block viral replication. These results
provide evidence that CDR-based synthetic peptides may exert a
potent control over R5 HIV-1 replication. They also point to a
difference in the biologic properties of the peptides in relation to
the HIV-1 viral strain used and probably also to the activation
state of PBMCs.
Antitumor activities of CDR-based synthetic peptides
All CDR peptides from all three mAbs were assayed for
cytotoxicity in B16F10-Nex2 murine melanoma cells. Although
most of them were inactive, C7/pc42 H2 inhibited 50% of tumor
cell growth at 0.05 mM; mAb HuA L1 was also effective but 5–10-
fold less inhibitory than C7/pc42 H2 (Table 5). MAb C7/pc42
H2 was equally cytotoxic to human melanoma cell lines SKmel-25
and SKmel-28 (Fig. 2A). Both C7/pc42 H2 and HuA L1 caused
DNA degradation in melanoma cells (Fig. 2B). The corresponding
scrambled peptides were inactive. Additional data confirmed that
both peptides were apoptotic not only in melanoma cells but also
in HL-60 leukemia cells. Apoptosis was caspase-dependent and
inhibitable by z-VAD, a pan-caspase inhibitor. Typical apoptotic
alterations were seen in HL-60 cells with surface blebs and nuclear
fragmentation (Fig. 2C).
Table 2. In vitro microbicidal activity of mAb C7/pc42 H2
alanine-substituted derivatives against Candida albicans.
asd1 Anti-Candida activity
EC50asd/
EC50H2
(%) at
100 mg/mL
EC50 (95% confidence
intervals) [mol/L]
Y1A 99.37 6.212 (3.668–10.507)61026 1.48
I2A 99.77 6.249 (0.416–93.929)61026 1.49
S3A 100.00 3.115 (3.114–3.115)61026 0.74
C4A 94.51 8.226 (6.911–9.790)61026 1.96
Y5A 98.10 2.853 (2.836–2.870)61025 6.81
N6A 100.00 1.542 (1.345–1.767)61026 0.37
G7A 100.00 7.312 (7.148–7.485)61026 1.74
T9A 100.00 3.798 (3.659–3.942)61026 0.91
S10A 100.00 1.324 (1.317–1.330)61025 3.16
Y11A 55.70 4.759 (3.798–5.961)61025 11.35
N12A 100.00 6.480 (5.231–8.031)61026 1.55
Q13A 100.00 3.912 (3.343–4.577)61026 0.93
K14A 91.72 1.850 (1.005–3.405)61025 4.41
F15A 100.00 9.039 (8.729–9.353)61027 0.22
K16A 0 1.608 (1.205–2.144)61024 38.35
1asd: alanine-substituted derivatives.
doi:10.1371/journal.pone.0002371.t002
Table 1. In vitro microbicidal activity of mAb C7, mAb pc42
and mAb HuA CDRs tested as synthetic peptides against
Candida albicans.
mAb CDR Anti-Candida activity
(%) at
100 mg/mL
EC50 (95% confidence
intervals) [mol/L]
C7 L1 KSSQSLLNSGNQKNYLT 100 1.523 (1.123–2.066)61025
C7 L2 WASTRES 49.8
C7 L3 NDYSYPRSR 99.3 2.019 (1.270–3.206)61025
C7/pc42 H1 GYYMH 69.2
C7/pc42 H2 YISCYNGATSYNQKFK 100 4.193 (3.416–5.146)61026
C7 H3 ARQGVRGGAMD 55.5
pc42 L1 YRASKSVSTSGYSYMH 100 7.801 (7.401–8.223)61027
pc42 L2 LVSNLES 100 1.196 (1.115–1.283)61025
pc42 L3 QHIRELTRSE 83.9
pc42 H3 PNPLKAM 25.9
HuA L1 RASQSVSSYLA 0
HuA L2 DASNRAT 0
HuA L3 QQRSNWPRS 100 5.109 (3.408–7.662)61026
HuA H1 SYTFH 12.9
HuA H2 VLAYDGSYQHYADSVKG 0
HuA H3 GQTTVTKIDEDY 19.2
doi:10.1371/journal.pone.0002371.t001
Table 3. Ex vivo and in vitro inhibitory activity (%) of synthetic
mAb C7, mAb pc42, and mAb HuA CDRs against HIV-1.
mAb CDR % inhibitory activity (10 mg/ml)
endogenous HIV-1
replication
exogenous HIV-1
replication
BaL IIIB
C7 L1 37 9 0
C7 L2 38 59 4
C7 L3 49 18 0
C7/pc42 H1 58 24 0
C7/pc42 H2 18 0 0
C7 H3 0 0 75
pc42 L1 91 41 0
pc42 L2 0 0 0
pc42 L3 0 0 0
pc42 H3 0 11 0
HuA L1 48 15 0
HuA L2 32 0 0
HuA L3 70 63 0
HuA H1 38 84 0
HuA H2 40 74 0
HuA H3 36 0 0
doi:10.1371/journal.pone.0002371.t003
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C7/pc42 H2 peptide is predicted to contain a beta amphipathic
(Eisenberg) region corresponding to SYNQKFK C-terminal
sequence. Alanine substitutions in this region, rather than on the
N-terminal (YISCYN) and turn region (GAT) reduced the
cytotoxicity of H2 (Table 6).
In vivo growth of tumor cells depends strictly on angiogenesis,
therefore CDR peptides were also tested for endothelial cell
cytotoxicity. The mAb C7 CDRs inhibited endothelial cell
sprouting as tested in vitro with HUVEC cells grown on
MatrigelTM. CDRs H2, and also L1, L2 and L3 at higher
concentrations, inhibited endothelial cell sprouting (Fig. 3A, B).
These results show that CDRs from the same mAb, but mostly H2
have a capacity to inhibit both tumor cell growth and endothelial
cell motility and tube formation.
Administration of mAb C7/pc42 H2 and mAb HuA L1
intraperitoneally showed antitumor effects in vivo in a model of
lung colonization by melanoma cells. While the untreated controls
had .300 black nodules in the lungs as a result of intravenous
injection of B16F10-Nex2 cells syngeneic to C57BL6 mice, the
peptide-treated animals had lungs with 34–40 nodules. A
significant increase in the survival time of peptide-treated animals
was observed; mice died several days after peptide treatment was
interrupted (Fig. 4A, B, C).
Discussion
CDR sequences in the variable regions of immunoglobulins are
thought to act cooperatively in the recognition of an antigen.
Among them, CDR H3 is at the center of antigen recognition, but
the other five CDRs are more or less involved for increased
binding affinity to the antigen and some contact residues can even
be located within framework regions [17]. The observation that
Ab specificity is determined by a limited number of residues has
allowed the synthesis of small peptides based on CDRs which
retain binding properties and functions of the intact Ab [18,19].
Diversity of CDR1 and CDR2 is encoded by the germline and
further modified by somatic mutation; that of CDR L3 and CDR
H3 arises somatically by rearrangement of the V segment with the
JL or DH and JH segments, respectively.
Isolated CDR sequences, frequently CDR H3, showed the same
specificity of the native Ab and were called micro(mini)antibodies
[20,21]. Diversity of CDR H3 is sufficient to allow otherwise
identical IgM molecules to distinguish between a variety of
haptens and protein antigens [22]. It has even been postulated that
diverse CDR3 loops represent a highly antigen specific recognition
core whereas other CDRs bind opportunistically [23]. Recently, a
tyrosine-sulfated peptide derived from CDR H3 of an HIV-1-
neutralizing Ab was shown to bind gp120 and inhibit HIV-1
infection [24]. Apart from the microantibodies that may display
anti-viral [25] and antitumor [26] activities as does the native Ab,
less is known about the biological activities of other CDR and
framework sequences tested as isolated peptides. Some CDR and
framework region-derived peptides, however, have been described
as inhibitors of receptor-ligand interactions, cell adhesion and of
microbial or viral infections [5,27]. Several peptides including
amino acids from the CDRs of anti-CD4 mAb ST40 and
framework residues flanking the CDRs bound to soluble CD4
and displaced Ab binding [28]. Bioactive paratope-derived
peptides of potential pharmacological interest were also deduced
by hydropathic complementarity [29].
Here we show that, independent of the specificity of the native
Ab, CDRs other than H3 may display, with high frequency,
antimicrobial, antiviral and antitumor activities in a way
reminiscent of molecules of early innate immunity [30]. Synthetic
peptides representing the CDRs of a native Ab (mAb C7), raised
against a C. albicans antigen, and also CDRs from mouse mAb
pc42, sharing H1 and H2 with mAb C7, and human mAb HuA,
sharing no CDR either with mAb C7 or mAb pc42, showed in
vitro, ex vivo and/or in vivo differential antimicrobial, antiviral and/
or antitumor activities.
The in vivo antitumor activity of mAb C7/pc42 H2 and mAb
HuA L1, the protection conferred by mAb C7/pc42 H1, H2 and
mAb C7 L1 against invasive candidiasis, as well as ex vivo inhibitory
activity of mAb pc42 L1 against HIV-1 are examples of
hypervariable Ab sequences with biological activity. Synthetic
peptides representing Ig CDRs are linear sequences with specific
binding properties. The high frequency of peptide binding in Ig
CDRs may reflect their increased diversity by somatic mutation
and clonal selection by antigens. Whether there may occur a
proteolytic release of active fragments from immunoglobulins is a
debatable hypothesis, that would be reminiscent of the extrinsic
activity of Hb33-61 from bovine haemoglobin that displays
antimicrobial activity against Gram-positive bacteria and fungi
at mM concentrations, as well as the carboxy-terminal tripeptide
(11-13, KPV) of a-MSH that inhibits Staphylococcus aureus, C.
albicans and HIV-1 at picomolar concentrations [31–33].
A wide variety of organisms, from single-cell microorganisms,
insects and other invertebrates, plants, amphibians, birds, fishes,
and mammals, man included, produce antimicrobial, antiparasitic
and antiviral peptides as part of their first line of defense [34]. As
evaluated by searching the Blast (National Center for Biotechnol-
ogy Information) data base, however, the sequences of the Ab
CDRs investigated in this study appear to be characteristic of
immunoglobulins and are very different from those of described
natural peptides.
Here, it is clear that C7/pc42 H2 and HuA L1 are directly
cytotoxic to tumor cells causing caspase-dependent apoptosis.
Apparently, the pro-apoptotic activity of C7/pc42 H2 on
melanoma cells depended on peptide binding to a surface receptor
that specifically recognizes the C-terminal sequence. The C-
terminal SYNQKFK peptide which is not apoptotic by itself
Table 4. Ex vivo inhibitory activity (%) of synthetic mAb C7
CDR H1 alanine-substituted derivatives against HIV-1.
mAb C7/pc42 H1 asd1 % inhibitory activity (10 mg/ml)
G1A 0
Y2A 61
Y3A 90
M4A 41
H5A 0
1asd: alanine-substituted derivatives.
doi:10.1371/journal.pone.0002371.t004
Table 5. In vitro antitumor activity of selected synthetic mAb
C7, mAb pc42, and mAb HuA CDRs against B16F10-Nex2
murine melanoma cells.
CDR EC50 (95% confidence intervals) [mol/L]
mAb C7/pc42 H2 5.35 (2.220–8.480)61025
mAb HuA L1 7.20 (6.666–7.734)61024
doi:10.1371/journal.pone.0002371.t005
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competed with and inhibited the cytotoxicity of mAb C7/pc42 H2
in melanoma cells (data not shown). Amino acids K14 and F15 are
crucial for the receptor-mediated mAb C7/pc42 H2 tumor cell
cytotoxicity. C7 H3 but not C7/pc42 H2 competed with mAb C7
for binding to phosphatidylcholine, the probable ligand of
polyreactive C7 on melanoma cells (unpublished results).
Apoptosis was characterized in both melanoma and HL-60
leukemia cells. H2 also inhibited endothelial cell growth on
MatrigelTM suggesting that its in vivo antitumor effect could also
involve inhibition of angiogenesis. Presently we show that both
peptides in the more stable C-terminal amidated form were active
against lung colonization by melanoma cells injected i.v. using a
protocol of i.p. administration every-other-day for 11 days. A
direct effect of peptides on tumor cells was needed for protection
since the suspension of treatment resulted in a delayed death curve
similar to the untreated control.
CDRs interference on HIV-1 replication was studied in PBMCs
exogenously infected with different viral strains and in a more
physiologic model of endogenously infected mononuclear cells.
Presently, we show that some CDR synthetic peptides were able to
inhibit R5 HIV-1 expression in naturally and exogenously infected
PBMCs. We speculate that the interaction between CDR
molecules and HIV-1 co-receptors CCR5 and CXCR4 in our
culture systems were, probably, the limiting factor for HIV-1
replication. An alignment analysis (http://www.ebi.ac.uk/cgi-bin/
clustalw) of the viral protein with the CDR sequences with high
antiviral activity showed that important peptide motifs of HuA L3
(QRSNWPR) and of pc42 L1 (SKSVSTSG) were present in
Figure 2. Antitumor effects of mAb CDRs. A. In vitro cytotoxic effects of C7/pc42 H2 in human melanoma cell lineages; B. DNA degradation in
B16F10-Nex2 cells induced by CDRs C7/pc42 H2 and HuA L1; S-C7H2 and S-HuaL1, scrambled peptides; STD, 1 Kb Plus DNA Ladder, Invitrogen; C.
Apoptotic response of HL-60 cells to peptides C7/pc42 H2 and HuA L1. HL-60 cells (56105) were treated with 0.5 mM of C7/pc42 H2 and HuA L1
peptides and incubated at 37uC. The material examined after 0, 3 and 6 h of incubation was collected by cytospin and stained (H&E). Peptide-treated
cells are shown with altered morphology, surface blebs, and nuclear fragmentation (arrows). N = cell nucleus; 1006magnification.
doi:10.1371/journal.pone.0002371.g002
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reverse transcriptase (RT) and Rev proteins, respectively. For
HIV-1 inhibition, it has already been reported that many peptides
could be competitive or non-competitive inhibitors of enzymatic
activities by structure mimicry or by hindering the formation of
enzyme-DNA/RNA complexes [35,36].
Possible molecular targets in Candida to reactive pc42 L1 and L2
and HuA L3 CDRs could be b-1,3/b-1,6 glucans that neutralize
these peptides as described for KP (data not shown). In the case of
C7 H2, an N-terminal sequence in ALS3 is hypothesized to be a
target based on its functional similarity with a peptide deduced by
hydropathic complementarity to C7 H2 with codons read in the
39–59 direction [37].
Additional pathogenic agents and tumor cell lines obtained from
type culture collections or isolated from clinical samples were also
sensitive in vitro to the inhibitory activity of mAb C7, pc42 and
HuA CDRs and engineered derivatives (unpublished data). They
include eukaryotic and prokaryotic microorganisms such as C.
neoformans, A. fumigatus, S. prolificans, Pseudomonas aeruginosa, methi-
cillin-resistant S. aureus, viruses such as influenza A Ulster 73
(H7N1) and human NWS (neurotropic H1N1) and tumor cell lines
HeLa (human cervix epitheloid carcinoma), CEM (human
leukemia), Hs294T (human melanoma).
The easy production and the low cost of small sized synthetic
peptides representing Ig CDRs may offer significant advantages
compared to recombinant Abs or Ab fragments for the rational
identification and design of novel antitumor, antimicrobial and
antiviral biologically active and therapeutic compounds. As we
demonstrated with KP and its D-isomeric form, such peptides can
be easily engineered and stabilized against proteolysis by
incorporation of non-natural amino acids or other modifications
without affecting, or even enhancing, their activity [7,38]. Peptide
engineering and chemical optimization associated to new delivery
mechanisms are expected to provide a new generation of
therapeutic agents in parallel to the peptide vaccines that aim at
protective immune responses [39].
Materials and Methods
Monoclonal antibodies and CDRs
Mouse mAb C7 (IgM), was produced as described elsewhere
[11]. Single-chain variable region Ab fragments were obtained
from the RNA extracted from the hybridoma cells secreting mAb
C7 (scFv C7) by using the phage display methodology, as
described [3]. After scFv C7 sequencing the CDRs of both light
and heavy chains were identified [40]. All the CDRs of mAb C7
were chemically synthesized.
The mouse mAb pc42 (IgM), was selected from the Basic Local
Alignment Search Tool (BLAST) of the National Center for
Biotechnology Information data base, searching for short, nearly
exact matches to the CDRs of mAb C7, as both mAbs shared the
same CDRs H1 and H2. MAb pc42 is directed to the dominant
epitope within a synthetic peptide model antigen (PS1CT3)
Table 6. In vitro antitumor activity of synthetic mAb C7/pc 42
H2 alanine-substituted derivatives against B16F10-Nex2
murine melanoma cells.
mAb C7/pc42 asd1
EC50 (95% confidence
intervals) [mol/L]
EC50asd/
EC50H2
Y1A 7.14 (3.587–10.693)61025 1.33
I2A 7.35 (3.847–10.853)61025 1.37
S3A 6.49 (4.751–8.229)61025 1.21
C4A 6.75 (3.222–10.278)61025 1.26
Y5A 7.35 (3.773–10.927)61025 1.37
N6A 7.69 (5.951–9.429)61025 1.44
G7A 6.32 (2.817–9.823)61025 1.18
T9A 6.02 (2.517–9.523)61025 1.13
S10A 1.19 (1.016–1.364)61024 2.22
Y11A 1.13 (0.954–1.306)61024 2.11
N12A 1.25 (1.163–1.337)61024 2.34
Q13A 1.28 (0.922–1.638)61024 2.39
K14A 3.84 (3.654–4.026)61024 7.18
F15A 1.00 (0.982–1.018)61023 18.69
K16A 8.7 (5.073–12.327)61025 1.63
1asd: alanine-substituted derivatives.
doi:10.1371/journal.pone.0002371.t006
Figure 3. Angiogenesis inhibition by mAb CDRs. A. Inhibition of
human endothelial cells (HUVEC) sprouting on MatrigelTM to form
closed intercellular pro-angiogenic structures by mAb C7 CDRs; dots
show individual rings. Untreated cell extensions are shown without and
with zooming (Z); B. Counting of pro-angiogenic structures after 16 h
incubation with peptides, in triplicate wells; *p, 0.01 relative to
untreated control.
doi:10.1371/journal.pone.0002371.g003
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including residues 28–42 of the large protein of the surface antigen
of hepatitis B virus containing a B cell epitope (PS1) and the
known T-helper lymphocyte epitope derived from the circum-
sporozoite protein of the malaria parasite P. falciparum (CT3) [15].
The hybridoma secreting mAb pc42 was kindly provided by Dr.
Kanury V.S. Rao (International Center for Genetic Engineering
and Biotechnology, New Delhi, India). As only the sequence of the
heavy chain with the corresponding CDRs (H1, H2, H3) had been
defined and published for mAb pc42, the genes encoding its light
chain were cloned and sequenced and the CDRs (L1, L2 and L3)
identified according to the procedures described for mAb C7.
Human mAb HuA (IgM) was secreted by a human-mouse
trioma cell line which was a cloned Epstein Barr virus-transformed
B cell line stabilized by fusion with the human-mouse fusion
partner SBC-H20. The VH and VL chain cDNAs of HuA had
been sequenced [16]. This Ab is representative of Abs widely
spread in the population and all its CDRs differed from those of
mAb C7 and mAb pc42. MAb HuA is specific for the most
frequent difucosylated human blood group A substances. All the
CDRs of mAb pc42 and mAb HuA were chemically synthesized.
The mAb C7/pc42 H2 and mAb HuA L1 scrambled peptides had
the sequences: QYKISCNKYTGSFNY and YARQVSSALSS,
respectively.
Engineering and evaluation of selected mAb C7 CDRs
The CDRs shared by mAb C7 and mAb pc42 (H1 and H2)
showing antimicrobial, antiviral and/or antitumor activity in vitro
or ex vivo were engineered by alanine-scanning. The alanine
substituted derivatives (asd), defined according to the position held
by the alanine-substituted aminoacid, were tested in the same
biological assays to critically establish the functional relevance of
each residue [5]. In vitro microbicidal activity of CDR peptides and
selected asd against C. albicans UP 10 (clinical isolate from the fungi
collection of the University of Parma) and C. albicans NCPF 3153
(National Collection of Pathogenic Fungi, Bristol, UK) were used
for the in vitro experiments.
The microbicidal activity of synthetic CDRs against C. albicans
strains was preliminarily evaluated by testing 100 mg/mL of each
synthetic peptide by colony forming unit (CFU) assays as
previously described [5]. Briefly, 10 mL of a distilled water
suspension containing ,56104/mL germinating yeast cells were
added to 90 mL of distilled water containing the synthetic peptide
to be tested. Yeast suspensions were incubated at 37uC for 6 h.
After incubation, the cell suspensions were plated on Sabouraud
dextrose agar, incubated at 30uC and observed for CFU
determination after 48–72 hours. Each assay was carried out in
triplicate. MAb CDR synthetic peptides exhibiting candidacidal
activity at 100 mg/mL, and asd of mAb C7/pc42 H2, selected for
the highest candidacidal activity, were further tested to determine
EC50 values. EC50 was calculated by nonlinear regression analysis
using Graph Pad Prism 4.01 software, San Diego, CA, USA.
In vivo evaluation of anti-Candida activity of CDR
peptides
Animal experiments were approved by the Institutional Review
Board of the School of Medicine and Odontology at the University
of the Basque Country, Spain. Female BALB/c mice, 8-weeks old
(11–12 animals/group), were infected intravenously with 56105 C.
albicans NCPF 3153 yeast cells suspended in 0.1 mL saline. Mice
were treated i.p. with 200 mg of mAb C7 L1 and mAb C7/pc42
H1 and H2 for 3 days starting on day 0, and 4 h after the fungal
challenge, and at 24 and 48 h thereafter. Control mice were
injected with saline (same treatment schedule as those treated with
the CDRs). Protection was evaluated by monitoring animal
Figure 4. In vivo antitumor effects of two apoptotic mAb CDRs.
A. In vivo protection (*p,0.001) by CDRs C7/pc42 H2 and HuA-L1
against lung colonization by B16F10-Nex2 melanoma cells (56105)
injected i.v. in C57Bl/6 mice (10 animals/group). Peptides were
administered (250 mg i.p.) on days 1, 3, 5, 7, 9, 11 after tumor cell
challenge. B. Lungs of peptide-treated animals after 23 days of tumor
challenge; CTL-control, untreated animals. C. Survival of peptide-
treated mice and PBS controls with treatment being interrupted after
day 11 of tumor cell i.v. challenge (p = 0.0014).
doi:10.1371/journal.pone.0002371.g004
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survival for 20 days. The mean survival time and numbers of CFU
of C. albicans in infected tissues were calculated as reported
previously [14].
Ex vivo and in vitro evaluation of the inhibitory activity of
CDR peptides and selected asd against HIV-1
Assessment of ex vivo antiviral activity of synthetic CDRs and asd
of mAb C7 H1, selected for the highest antiviral activity in HIV-1
endogenous infection was performed as previously described
[10,41]. Briefly, for endogenous HIV-1 replication assays
peripheral blood mononuclear cells (PBMCs) from R5 HIV-1-
infected patients characterized by high viral RNA titers in plasma
and cell-associated viremia were cultured in 96-well plates at
16106 cells/mL in RPMI 1640 medium with 10% fetal calf serum
(FCS) and 20 U/mL of rIL-2. Exogenous rIL-2 was added every
3–4 days. Cultures were treated with synthetic mAb CDRs and
mAb C7/pc42 H1 asd at 10 mg/mL during the time of culture.
Virus production on days 5 and 10 was assayed in the supernatants
using ultrasensitive AllianceH HIV-1 p24 ELISA kit (Perkin
Elmer); p24 Ag in the supernatants of untreated cultures
corresponded to 100% of viral production. For exogenous
infection assays, PHA-stimulated PBMCs obtained from healthy
individuals were infected with BaL (R5) or IIIB (X4) HIV-1 strain
at a median tissue culture infective dose (TCID50) of 500 TCID50/
ml. After 2 h of adsorption, the cells were washed, suspended at
26105 cells/ml in medium and cultured in 96-well cultures plates.
At time zero of infection, synthetic peptides were added to the
cultures at 10 mg/ml and were maintained throughout the
experiment. All assays were performed in triplicate. Virus
production was assayed 10 days after infection in the supernatants
of HIV-1-infected PBMCs by p24 assay.
Tumor cell lines and cell culture
Murine B16F10-Nex2 melanoma cells (cloned at the Experi-
mental Oncology Unit, Federal University of Sa˜o Paulo,
UNIFESP), and human SKmel28 and SKmel25 human melano-
ma cell lines originally obtained from the Memorial Sloan
Kettering Cancer Center, New York, were cultured at 37uC,
under humid atmosphere and 5% CO2, in RPMI-1640 medium
with 10 mM N-2-hydroxyethylpiperazine-N2 ethanesulphonic
acid (HEPES), 24 mM sodium bicarbonate, 40 mg/L gentamycin,
pH 7.2 and 10% FCS.
In vitro tumor cytotoxic activity of CDR peptides and
selected asd
Synthetic CDRs, scrambled peptides (controls), and asd of mAb
C7/pc42 H2, selected for the highest cytotoxic activity, were
diluted from 1 mM to 0.05 mM in RPMI with 10% FCS and
incubated with B16F10-Nex2, SKmel28 and SKmel25 cells
(56103 cells/well) in 100 mL per well for 12 h at 37uC. Each
peptide was tested in triplicate. After 12 h, the cytotoxic activities
of the peptides were determined by measuring cell viability by
Trypan Blue exclusion. A 50% inhibition of cell growth was taken
as a comparative index of cytotoxicity (EC50).
DNA fragmentation assay
B16F10 cells were grown for 24 h in 12-well plates (105cells/
well), and then were further incubated for 12 h at 37uC with mAb
C7/pc42 H2 (0.3 mM) and mAb HuA L1 (0.6 mM). Cells were
then collected in phosphate-buffered saline-EDTA (PBS-0.02%
EDTA), and centrifuged at 1,500 rpm. The pellets were
suspended in 500 mL of TELT buffer [42] [50 mM Tris-HCl
(Gibco), 4% Triton X-100 (LKB), 2.5 mM EDTA, pH 9.0
(Pharmacia) and 2.5 M LiCl (Merck)], pH 8.0. After centrifuga-
tion, equal volume of phenol (Gibco, pH 7.49–7.79) was added to
the supernatant and centrifuged at 12,000 g/30 minutes. The
aqueous phase was transferred to a new tube and equal volume of
chloroform was added (Merck). After centrifugation (15 min,
12,000 g), equal volume of isopropanol was added to the pellet
and cooled at 220uC for 24 h. The sample was centrifuged at
12,000 g/15 min, and the pellet washed with 500 mL of ethanol
70% (Merck). The dry pellet was resuspended in water with
RNAse (20 mg/mL). Degradation of DNA in a ladder profile [43]
was assessed in 0.8% Agarose gel electrophoresis (Pharmacia).
In vitro Matrigel angiogenesis assay
MatrigelTM Matrix (B&D Biosciences, Bedford, MA, USA) was
thawed on ice, added (10 mL/well) to coat 96-well plates, and
allowed to polymerize for 1 h at 37uC. Human umbilical vein
endothelial cells (HUVEC) (56103cells/well) were added alone or
mixed with mAb C7 CDR peptides in 100 mL of RPMI medium
supplemented with 0.2% of FCS in each well. All peptides were
used at 1 mM, with the exception of mAb C7/pc42 H2 that was
used at 50 mM. The plates were incubated at 37uC for 18 h and
images were captured at 86magnification with a Sony Cyber-shot
camera coupled to a light microscope. The number of pro-
angiogenic structures (closed rings formed at a given time by
endothelial cell sprouting) was counted from 3 different wells, and
the average value determined in each system [44,45]. The assay
was repeated at least three times.
In vivo tumor protection assays with CDR peptides
All animal experiments were carried out using protocols
approved by the Ethics Committee for animal experimentation
of Federal University of Sa˜o Paulo, Brazil. Thirty male C57BL/6
mice seven-to eight-week-old were injected i.v. with 56105
syngeneic B16F10-Nex2 viable cells in 0.1 mL for each mouse.
For protection experiments three groups of 10 animals received on
days 1, 3, 5, 7, 9, 11 after tumor cell challenge, i.p. doses of 250 mg
of mAb C7/pc42 H2 and of mAb HuA L1, or PBS, at the same
time periods, respectively. After 23 days, the lungs were collected
from half of the animals of each group and inspected for metastatic
colonization and the melanotic nodules were counted at 26
magnification. The survivals of remaining peptide-treated mice
and controls were recorded till 40 days after i.v. challenge of tumor
cells.
Statistical analysis
The Kaplan-Meier log rank test was applied to survival data.
Data on CFU in infected tissues were analyzed by Student’s t test.
p values of 0.05 were considered significant.
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